A/Prof Annette Lim
Honorary Conjoint Principal Fellow
The Sir Peter MacCallum Department of Oncology
64 Scholarly works
0 Projects
HIGHLIGHTS
2026
Journal article
Extended follow-up outcomes of patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab on EMPOWER-CSCC-1: A retrospective cohort study
DOI: 10.1016/j.jaad.2025.11.0802026
Journal article
Adjuvant nivolumab for resected high-risk head and neck cancer
DOI: 10.1016/S0140-6736(26)00133-92025
Journal article
Evaluating CD103 intratumoral immune cell abundance and PD-L1 CPS in primary tumors versus lymph nodes in Human papillomavirus associated oropharyngeal Cancer
DOI: 10.1016/j.oraloncology.2025.1077922025
Journal article
Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors
DOI: 10.1136/jitc-2025-0118652025
Journal article
1603MO Analysis of second primary cutaneous squamous cell carcinoma (CSCC) tumors (SPTs) reported during the C-POST trial, a randomized phase III study of adjuvant cemiplimab vs placebo (pbo) for high-risk CSCC
DOI: 10.1016/j.annonc.2025.08.22312025
Journal article
Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma
DOI: 10.1056/NEJMoa25024492025
Journal article
Impact of Adjuvant Cemiplimab in High-Risk Cutaneous Squamous Cell Carcinoma
DOI: 10.3390/curroncol32080459
RECENT SCHOLARLY WORKS
2025
Journal article
Patient-reported outcomes (PROs) in the C-POST trial of adjuvant cemiplimab (cemi) vs placebo (pbo) for high-risk cutaneous squamous cell carcinoma (CSCC).
DOI: 10.1200/jco.2025.43.16_suppl.60652025
Journal article
Radiological, Pathological, and Surgical Outcomes with Neoadjuvant Cemiplimab for Stage II–IV Cutaneous Squamous Cell Carcinoma in the Deep Sequencing in Cutaneous Squamous Cell Carcinomas (DISCERN) Trial
DOI: 10.3390/cancers171017272025
Journal article
Cemiplimab in the treatment of cutaneous squamous cell carcinoma
DOI: 10.1080/1750743X.2026.2619658